ARTICLE

FindCenter AddIcon

Progress Toward a Safer Psychedelic Drug to Treat Depression and Addiction

By Jon Hamilton — 2020

A chemically tweaked version of the psychedelic drug ibogaine appears to relieve depression and addiction symptoms without producing hallucinations or other dangerous side effects.

Read on www.npr.org

FindCenter Post-Image

Psychedelics and Race: A Profile of Dr. Monnica T. Williams

The exuberant “renaissance” of studies researching psychedelic-assisted psychotherapy in the past twenty years has not sufficiently included the enrollment of racially diverse participants, a problem that psychedelic science and clinical research shares with mainstream psychiatry

Article
Patricia Kubala
2020
FindCenter AddIcon
FindCenter Post-Image

Introducing Ayahuasca

Amazonian healing traditions collide with Western medical sensibilities.

Article
Zoe Jahn, Monnica T. Williams
2019
FindCenter AddIcon
FindCenter Post-Image

Psychedelic Drugs Can Help Treat PTSD Caused by Racism, Discrimination: Researchers

Williams is the co-lead author of a recent retrospective study that found those who tried doses of psilocybin (more commonly known as magic mushrooms), LSD, or MDMA (the pure substance found in Ecstasy or Molly) reported a decrease in trauma symptoms, depression and anxiety after 30 days.

Article
Avis Favaro, Elizabeth St. Philip, Solarina Ho
2021
FindCenter AddIcon

EXPLORE TOPIC

Ibogaine